Daiichi Sankyo avoids payout in long-running patent dispute with Pfizer’s Seagennews2025-12-04T11:59:37+00:00December 4th, 2025|Endpoints News|
Hospitals challenge 340B rebate pilot program in Maine federal courtnews2025-12-02T20:24:15+00:00December 2nd, 2025|Endpoints News|
New York judge revives Bristol Myers dispute over Celgene dealnews2025-12-02T20:12:11+00:00December 2nd, 2025|Endpoints News|
House passes bill to reauthorize rare pediatric PRV program; Senate nextnews2025-12-02T03:29:54+00:00December 2nd, 2025|Endpoints News|
Sanofi headquarters raided in broader French tax fraud investigationnews2025-11-26T11:46:20+00:00November 26th, 2025|Endpoints News|
Pharma faces deadline to bring IRA fight to Supreme Court as first set of negotiated prices loomsnews2025-11-25T17:32:39+00:00November 25th, 2025|Endpoints News|
Teva loses IRA drug pricing challenge in DC federal court news2025-11-21T19:19:47+00:00November 21st, 2025|Endpoints News|
GSK, AnaptysBio enter legal battle over decade-old Jemperli licensing dealnews2025-11-21T12:07:36+00:00November 21st, 2025|Endpoints News|
AbbVie, Novartis can proceed with legal fight against Utah 340B lawnews2025-11-20T15:40:44+00:00November 20th, 2025|Endpoints News|
Drugmakers say HHS’ 340B pilot is limited as they fight for their own rebate modelsnews2025-11-17T21:00:33+00:00November 17th, 2025|Endpoints News|
